Long-COVID Therapies:
NAD+ IV Therapy

By Tabitha Block, Jonathann Kuo MD

What is NAD+?

NAD is the abbreviation for a compound called nicotinamide adenine dinucleotide, which is well-known for its critical role in energy production. NAD is also involved in the smooth execution of signaling pathways that govern proper functioning of the immune system and cell survival. NAD+, a form of NAD, is responsible for many of these biological functions. As we age, DNA damage from toxin accumulation, ultraviolet light exposure and other stressors cause levels of NAD+ in the body to decline. In addition to the natural decline of NAD+ levels that occurs with aging, many disease states associated with increased oxidative stress cause a reduction of NAD+ levels (28). Under normal conditions, reactive oxygen species (ROS) are produced by many cellular processes, such as oxygen metabolism and antimicrobial activities. These compounds are typically cleared or counteracted by enzymes, but ROS can accumulate if these antioxidant mechanisms are impaired, causing DNA damage and a subsequent reduction of NAD+ levels (29, 30). 

Reduced levels of NAD+ have been shown to cause altered metabolic states and increased disease susceptibility. The consequences of insufficient levels of NAD+ have been widely studied in the context of age-related disorders and neurodegenerative diseases (30-31). More recently, however, research suggests these consequences may contribute to the extensive biological abnormalities seen across the SARS-CoV-2 disease spectrum (32). Early data indicate that NAD+ repletion therapy may reduce symptoms of long COVID (33).

How does NAD+ IV Therapy help reduce long COVID Symptoms?

Enzymes are a type of protein that help speed up chemical reactions in the body. Normally, enzyme production is under tight control to ensure that products are not wasted through excessive synthesization and substrates are not used up too quickly. Many enzymes and proteins depend on NAD+ to carry out their respective functions. For example, some NAD+-dependent enzymes are required for the antiviral activity of the interferon system, an immune response to viral infection (34). Enzymes involved in the interferon system rely on a supply of NAD+ to carry out antiviral responses (34-35). During many viral infections, the NAD+ supply required by the interferon system is undisrupted and the immune system can adequately respond (34). When a person’s cells become infected with SARS-CoV-2, the virus that causes COVID and long COVID, the composition of enzymes produced by the cell’s protein synthesizing machinery drastically changes. Recent research has shown that the SARS-CoV-2 virus stimulates the infected cells to increase the synthesis of NAD+-consuming enzymes which preferentially provide NAD+ to viral activities (35-37). The NAD+-consuming enzymes which become upregulated in SARS-CoV-2 infection cause a severe depletion of available NAD+ (36-37). Without an adequate supply of NAD+, the NAD+-dependent enzymes of the interferon system cannot properly function, leading to impaired antiviral activity (34-37). Further, dysregulation of NAD+ metabolism has been shown to have a wide range of health implications from compromised cardiac function to hyperinflammation and DNA damage due to increased oxidative stress (38).

Although the consequences of SARS-CoV-2-mediated NAD+ depletion are not yet fully understood, preclinical and clinical data has suggested NAD+ supplementation may accelerate recovery from long COVID (39-40). NAD+ supplementation has been shown to increase the body’s resilience to many different diseases. Physician-guided intravenous administration of NAD+ may safely provide direct and effective symptom relief of long COVID symptoms involving NAD+-depletion.

Please see this linked article that we are publishing that summarizes our current understanding of this process. 

What happens during NAD+ IV Therapy?

NAD+ can be administered orally or intravenously, but intravenous administration results in higher concentrations of NAD+ in the bloodstream (21). Prior to your infusion, you will have a consultation with your physician, who will carefully consider your medical history and present symptoms to determine if you are a candidate for NAD+ IV Infusion Therapy. If you are an appropriate candidate, our staff will help you get comfortably set up in one of our infusion rooms. During a NAD+ IV Infusion treatment, one of our highly experienced staff members will place an IV in your arm or hand, which will remain throughout the duration of the therapy. Over the course of 45 minutes to 1 hour, NAD+ will be administered through an IV drip with normal saline.

  1. Raveendran, A V et al. “Long COVID: An overview.” Diabetes & metabolic syndrome vol. 15,3 (2021): 869-875. doi:10.1016/j.dsx.2021.04.007

  2. Carfì, Angelo et al. “Persistent Symptoms in Patients After Acute COVID-19.” JAMA vol. 324,6 (2020): 603-605. doi:10.1001/jama.2020.12603

  3. Forte, Giuseppe et al. “COVID-19 Pandemic in the Italian Population: Validation of a Post-Traumatic Stress Disorder Questionnaire and Prevalence of PTSD Symptomatology.” International journal of environmental research and public health vol. 17,11 4151. 10 Jun. 2020, doi:10.3390/ijerph17114151

  4. Jiang Hj, Nan J, Lv Zy, Yang J. Psychological impacts of the COVID-19 epidemic on Chinese people: Exposure, post-traumatic stress symptom, and emotion regulation. Asian Pac J Trop Med 2020;13:252-9

  5. Lipov, Eugene G et al. “A unifying theory linking the prolonged efficacy of the stellate ganglion block for the treatment of chronic regional pain syndrome (CRPS), hot flashes, and posttraumatic stress disorder (PTSD).” Medical hypotheses vol. 72,6 (2009): 657-61. doi:10.1016/j.mehy.2009.01.009

  6. Moon HS, Chon JY, Lee SH, Ju YM, Sung CH. Long-term Results of Stellate Ganglion Block in Patients with Olfactory Dysfunction. Korean J Pain. 2013;26(1):57-61. doi:10.3344/kjp.2013.26.1.57

  7. Barizien, N., Le Guen, M., Russel, S. et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep 11, 14042 (2021). https://doi.org/10.1038/s41598-021-93546-5

  8. Dani, Melanie et al. “Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies.” Clinical medicine (London, England) vol. 21,1 (2021): e63-e67. doi:10.7861/clinmed.2020-0896

  9. Lipov, Eugene G et al. “Stellate ganglion block improves refractory post-traumatic stress disorder and associated memory dysfunction: a case report and systematic literature review.” Military medicine vol. 178,2 (2013): e260-4. doi:10.7205/MILMED-D-12-00290

  10. Lynch, James H. “Stellate ganglion block treats posttraumatic stress: An example of precision mental health.” Brain and behavior vol. 10,11 (2020): e01807. doi:10.1002/brb3.1807

  11. Summers, Mary R, and Remington L Nevin. “Stellate Ganglion Block in the Treatment of Post-traumatic Stress Disorder: A Review of Historical and Recent Literature.” Pain practice : the official journal of World Institute of Pain vol. 17,4 (2017): 546-553. doi:10.1111/papr.12503

  12. Mulvaney, Sean W et al. “Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients.” Military medicine vol. 179,10 (2014): 1133-40. doi:10.7205/MILMED-D-14-00151

  13. “How SGB Works.” Stella Center, https://stellacenter.com/.

  14. Tian, Ying et al. “Effective Use of Percutaneous Stellate Ganglion Blockade in Patients With Electrical Storm.” Circulation. Arrhythmia and electrophysiology vol. 12,9 (2019): e007118. doi:10.1161/CIRCEP.118.007118

  15. Datta, Rashmi et al. “A study of the efficacy of stellate ganglion blocks in complex regional pain syndromes of the upper body.” Journal of anaesthesiology, clinical pharmacology vol. 33,4 (2017): 534-540. doi:10.4103/joacp.JOACP_326_16

  16. Liu LD, Duricka DL. Stellate ganglion block reduces symptoms of Long COVID: A case series. J Neuroimmunol. 2022;362:577784. doi:10.1016/j.jneuroim.2021.577784

  17. Moon HS, Chon JY, Lee SH, Ju YM, Sung CH. Long-term Results of Stellate Ganglion Block in Patients with Olfactory Dysfunction. Korean J Pain. 2013;26(1):57-61. doi:10.3344/kjp.2013.26.1.57

  18. Carr, Anitra C, and Silvia Maggini. “Vitamin C and Immune Function.” Nutrients vol. 9,11 1211. 3 Nov. 2017, doi:10.3390/nu9111211

  19. Halliwell, B. “Antioxidants in human health and disease.” Annual review of nutrition vol. 16 (1996): 33-50. doi:10.1146/annurev.nu.16.070196.000341

  20. ​​Bae, Minkyung, and Hyeyoung Kim. “Mini-Review on the Roles of Vitamin C, Vitamin D, and Selenium in the Immune System against COVID-19.” Molecules (Basel, Switzerland) vol. 25,22 5346. 16 Nov. 2020, doi:10.3390/molecules25225346

  21. Hoang, Ba X et al. “Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection.” Journal of global antimicrobial resistance vol. 23 (2020): 256-262. doi:10.1016/j.jgar.2020.09.025

  22. Fritz, Heidi et al. “Intravenous Vitamin C and Cancer: A Systematic Review.” Integrative cancer therapies vol. 13,4 (2014): 280-300. doi:10.1177/1534735414534463

  23. Klaunig, James E. “Oxidative Stress and Cancer.” Current pharmaceutical design vol. 24,40 (2018): 4771-4778. doi:10.2174/1381612825666190215121712

  24. Pignatelli, Pasquale et al. “Oxidative stress and cardiovascular disease: new insights.” Kardiologia polska vol. 76,4 (2018): 713-722. doi:10.5603/KP.a2018.0071

  25. Wood, Emily et al. “Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: A possible approach to SARS-CoV-2 ‘long-haulers’?.” Chronic diseases and translational medicine vol. 7,1 (2021): 14-26. doi:10.1016/j.cdtm.2020.11.002

  26. Vollbracht, Claudia, and Karin Kraft. “Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue.” Nutrients vol. 13,4 1154. 31 Mar. 2021, doi:10.3390/nu13041154

  27. Pierce, Janet D et al. “Post-COVID-19 Syndrome.” Nursing research, 10.1097/NNR.0000000000000565. 12 Oct. 2021, doi:10.1097/NNR.0000000000000565

  28. Miller, R et al. “COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity.” Medical hypotheses vol. 144 (2020): 110044. doi:10.1016/j.mehy.2020.110044

  29. Braidy, Nady, and Yue Liu. “NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.” Experimental gerontology vol. 132 (2020): 110831. doi:10.1016/j.exger.2020.110831

  30. Johnson, Sean, and Shin-Ichiro Imai. “NAD + biosynthesis, aging, and disease.” F1000Research vol. 7 132. 1 Feb. 2018, doi:10.12688/f1000research.12120.1

  31. Rajman, Luis et al. “Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.” Cell metabolism vol. 27,3 (2018): 529-547. doi:10.1016/j.cmet.2018.02.011

  32. Forcados, Gilead Ebiegberi et al. “Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants.” Frontiers in cellular and infection microbiology vol. 11 654813. 26 May. 2021, doi:10.3389/fcimb.2021.654813

  33. Altay, Ozlem et al. “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) vol. 8,17 (2021): e2101222. doi:10.1002/advs.202101222

  34. Tan, Arnold, and Craig L Doig. “NAD+ Degrading Enzymes, Evidence for Roles During Infection.” Frontiers in molecular biosciences vol. 8 697359. 16 Aug. 2021, doi:10.3389/fmolb.2021.697359

  35. Dantoft, Widad et al. “Metabolic Regulators Nampt and Sirt6 Serially Participate in the Macrophage Interferon Antiviral Cascade.” Frontiers in microbiology vol. 10 355. 4 Mar. 2019, doi:10.3389/fmicb.2019.00355

  36. Brenner, C. “Viral infection as an NAD+ battlefield.” Nat Metab (2022). https://doi.org/10.1038/s42255-021-00507-3

  37. Heer, Collin D et al. “Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.” The Journal of biological chemistry vol. 295,52 (2020): 17986-17996. doi:10.1074/jbc.RA120.015138

  38. Katrina Bogan-Brown, Yasmeen Nkrumah-Elie, Yusrah Ishtiaq, Philip Redpath & Andrew Shao (2021) “Potential Efficacy of Nutrient Supplements for Treatment or Prevention of COVID-19.” Journal of Dietary Supplements, DOI: 10.1080/19390211.2021.1881686

  39. Altay, Ozlem et al. “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) vol. 8,17 (2021): e2101222. doi:10.1002/advs.202101222

  40. National Library of Medicine (U.S.). (2020, October – ). Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome. Identifier NCT04604704. https://clinicaltrials.gov/ct2/show/NCT04604704

  41. Popowski, Kristen et al. “Exosome therapeutics for lung regenerative medicine.” Journal of extracellular vesicles vol. 9,1 1785161. 29 Jun. 2020, doi:10.1080/20013078.2020.1785161

  42. Muthu, Sathish et al. “Exosomal therapy-a new frontier in regenerative medicine.” Stem cell investigation vol. 8 7. 2 Apr. 2021, doi:10.21037/sci-2020-037

  43. Lee, Changjin et al. “Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.” Circulation vol. 126,22 (2012): 2601-11. doi:10.1161/CIRCULATIONAHA.112.114173

  44. Panagiotou, Nikolaos et al. “Extracellular Vesicles, Ageing, and Therapeutic Interventions.” Cells vol. 7,8 110. 18 Aug. 2018, doi:10.3390/cells7080110

  45. Di Matteo, B et al. “Minimally Manipulated Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Systematic Review of Clinical Evidence.” Stem cells international vol. 2019 1735242. 14 Aug. 2019, doi:10.1155/2019/1735242

  46. Sengupta, Vikram et al. “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.” Stem cells and development vol. 29,12 (2020): 747-754. doi:10.1089/scd.2020.0080

  47. Ren, Jinxuan et al. “Mesenchymal Stem Cells and their Exosomes: Promising Therapeutics for Chronic Pain.” Current stem cell research & therapy vol. 14,8 (2019): 644-653. doi:10.2174/1574888X14666190912162504

  48. Hade, Mangesh D et al. “Mesenchymal Stem Cell-Derived Exosomes: Applications in Regenerative Medicine.” Cells vol. 10,8 1959. 1 Aug. 2021, doi:10.3390/cells10081959

  49. Bakhtyar, Nazihah et al. “Acellular Gelatinous Material of Human Umbilical Cord Enhances Wound Healing: A Candidate Remedy for Deficient Wound Healing.” Frontiers in physiology vol. 8 200. 4 Apr. 2017, doi:10.3389/fphys.2017.00200

  50. Shabbir, Arsalan et al. “Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro.” Stem cells and development vol. 24,14 (2015): 1635-47. doi:10.1089/scd.2014.0316

  51. Zhang, Jieyuan et al. “Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis.” Journal of translational medicine vol. 13 49. 1 Feb. 2015, doi:10.1186/s12967-015-0417-0

  52. Bazdyrev, Evgeny et al. “Lung Fibrosis after COVID-19: Treatment Prospects.” Pharmaceuticals (Basel, Switzerland) vol. 14,8 807. 17 Aug. 2021, doi:10.3390/ph14080807

  53. Udwadia, Zarir F et al. “Post-COVID lung fibrosis: The tsunami that will follow the earthquake.” Lung India : official organ of Indian Chest Society vol. 38,Supplement (2021): S41-S47. doi:10.4103/lungindia.lungindia_818_20

  54. Bernardo, Maria Ester, and Willem E Fibbe. “Mesenchymal stromal cells: sensors and switchers of inflammation.” Cell stem cell vol. 13,4 (2013): 392-402. doi:10.1016/j.stem.2013.09.006

  55. Mitrani, Maria Ines et al. “Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic.” Respiratory medicine case reports vol. 34 (2021): 101502. doi:10.1016/j.rmcr.2021.101502

  56. “Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome.” Direct Biologics. June 9, 2021. https://directbiologics.com/direct-biologics-receives-fda-approval-second-exoflo-ind-for-post-acute-covid-19/. Date Accessed: January 12, 2022. 



Explore Long-COVID Treatments

Stellate Ganglion Blocks (SGB)

Vitamin C IV Therapy

Exosome IV Therapy